RecruitingNCT04394871
Rare condition
Amyotrophic lateral sclerosis type 4
1
studies recruiting now
as of 7 Sept 2026
2
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
20 May 2020
most recent study posted
among recruiting studies
Recruiting trials
Showing the 1 most recently updated recruiting study, as recorded 7 Sept 2026. Live status on each study page.
Search all Amyotrophic lateral sclerosis type 4 studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Amyotrophic lateral sclerosis type 4 study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Amyotrophic lateral sclerosis type 4
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (SETX).
Treatments being studied
4 approved treatments and 125 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tofersen (Qalsody)Approved: Edaravone (Radicava)Approved: Riluzole (Exservan)Approved: Mecobalamin (Asimil b-12)
Phase 3Quinidine
Phase 3Creatine
Phase 3Dolutegravir
Phase 3Ceftriaxone
Phase 3Masitinib (Kinavet)
Phase 3Taurolithocholic Acid
Phase 3Arimoclomol
Phase 3Dextromethorphan
+ 117 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).